Advertisement

American Journal of Clinical Dermatology

, Volume 16, Issue 2, pp 111–123 | Cite as

The Medical and Laser Management of Hidradenitis Suppurativa

  • Rosalind Hughes
  • Genevieve Kelly
  • Cheryl Sweeny
  • Aoife Lally
  • Brian Kirby
Review Article

Abstract

Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease characterized by painful recurrent nodules and abscesses. In advanced stages, sinus tracts form, with resulting fibrotic and cribriform scar formation, leading to dermal contractures and induration of the affected skin. The epidemiology of HS is poorly described, and few population-based studies exist. The reported incidence varies from 0.0003 to 4 %. Effective treatment options for HS are limited, and randomized controlled trials addressing the safety and/or efficacy of available treatments are scarce. No medical treatment to date has been approved by the US FDA specifically for the treatment of HS. While some evidence of disease improvement exists with agents including clindamycin and rifampicin, metformin, fumarates, infliximab, and adalimumab, no single treatment has shown overwhelmingly positive outcomes. The lack of randomized controlled trials for most treatments and often disappointing treatment outcomes is disheartening. This study reviews the published evidence for treatment options for HS.

Keywords

Metformin Infliximab Adalimumab Dapsone Anakinra 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosures

The authors confirm that no funding was received in relation to the writing of this article.

The authors, Dr. Rosalind Hughes, Dr. G Kelly, Dr. A Lally, and Dr. C Sweeny do not have any relevant conflicts of interest to disclose.

Professor Brian Kirby has received research grants from the following: Pfizer, Abbvie and Merck-Sharp-Dohme. He has also worked as a consultant and advisor for the following: Pfizer, Abbvie, Roche, Merck Sharpe & Dohme, Novartis and Jansen.

References

  1. 1.
    Anderson MJ, Dockerty MB. Perianal hidradenitis suppurativa. Dis Colon Rectum. 1958;1(1):23–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Slade DE, Powell B, Mortimer P. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. 2003;56(5):451–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Danby FW, Jemec GBE, Marsch WC, von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol. 2013;168(5):1034–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164(2):367–71.CrossRefGoogle Scholar
  5. 5.
    Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990;122(6):763–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2 Pt 1):191–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97–103.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Jemec GB, Faber M, Gutschik E, Wendelboe P. The bacteriology of hidradenitis suppurativa. Dermatology. 1996;193(3):203–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Sartorius K, Killasli H, Oprica C, Sullivan A, Lapins J. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166(4):879–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Highet AS. Bacteriology and antibiotic treatment of perineal suppurative hidradenitis. Arch Dermatol. 1988;124(7):1047 (American Medical Association).CrossRefPubMedGoogle Scholar
  11. 11.
    Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol. 1999;140(1):90–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Brenner D, Lookingbill D. Anaerobic microorganisms in chronic suppurative hidradenitis. Lancet. 1980;316(8200):921–2.CrossRefGoogle Scholar
  13. 13.
    Bendahan J, Paran H, Kolman S, Neufeld DM, Freund U. The possible role of Chlamydia trachomatis in perineal suppurative hidradenitis. Eur J Surg. 1992;158(4):213–5.PubMedGoogle Scholar
  14. 14.
    Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Jemec GBE, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol. 2012;148(4):439–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Buimer MG, Ankersmit MFP, Wobbes T, Klinkenbijl JHG. Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a prospective randomized study. Dermatol Surg. 2008;34(2):224–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol. 1998;139 Suppl:37–40.CrossRefGoogle Scholar
  19. 19.
    Scheinfeld N. Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2013;19(4):1.PubMedGoogle Scholar
  20. 20.
    Polano MK, August PJ. Topical skin therapeutics. Edinburgh: Churchill Livingstone; 1984.Google Scholar
  21. 21.
    Boer J, Jemec GBE. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010;35(1):36–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Sartorius K, Boer J, Jemec GB. “Topical treatment”. In: Jemec GBE, Revuz J, Leyden JJ, editors. Hidradenitis suppurativa. Springer: Berlin Heidelberg; 2006. p. 150–60. Google Scholar
  23. 23.
    Mendonça CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154(5):977–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148–54.CrossRefPubMedGoogle Scholar
  25. 25.
    Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28(1):125–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Van der Zee HH, Boer J, Prens EP, Jemec GBE. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219(2):143–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Join-Lambert O, Coignard H, Jais J-P, Guet-Revillet H, Poirée S, Fraitag S, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011;222(1):49–58.CrossRefPubMedGoogle Scholar
  28. 28.
    Goldsmith PC, Dowd PM. Successful therapy of the follicular occlusion triad in a young woman with high dose oral antiandrogens and minocycline. J R Soc Med. 1993;86(12):729–30.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Harvath L, Yancey KB, Katz SI. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol. 1986;137(4):1305–11.PubMedGoogle Scholar
  30. 30.
    Martin WJ, Kachel DL. Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Am Rev Respir Dis. 1985;131(4):544–7.PubMedGoogle Scholar
  31. 31.
    Hofer T, Itin PH. Acne inversa: a dapsone-sensitive dermatosis. Hautarzt. 2001;52(10 Pt 2):989–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatol Treat. 2006;17(4):211–3.CrossRefGoogle Scholar
  33. 33.
    Yazdanyar S, Boer J. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222(4):342–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Kozub P, Simaljakova M. Hidradenitis suppurativa treated with combination of infliximab and dapsone. Bratisl Lek Listy. 2012;113(5):319–23.PubMedGoogle Scholar
  35. 35.
    Nassif A, Coignard H, Join-Lambert O, Lortholary O. Complete remission of severe hidradenitis suppurativa obtained in 4 patients using wide-spectrum antimicrobial treatment. J Am Acad Dermatol. 2012;66(4):AB46 (Poster reference number 5181) (Abstract).Google Scholar
  36. 36.
    Gül HC, Coşkun O, Savaşci U, Ors F, Beşirbellioğlu AB, Eyigün CP. A case of meningitis emerged as a complication of hidradenitis suppurativa. Mikrobiyol Bul. 2009;43(1):153–7.PubMedGoogle Scholar
  37. 37.
    Deckers IE, van der Zee HH, Balak DMW, Prens EP. Fumarates, a new treatment option for therapy resistant hidradenitis suppurativa: a prospective open-label pilot study. Br J Dermatol. 2014 Aug 13. doi: 10.1111/bjd.13346.
  38. 38.
    Norris JF, Cunliffe WJ. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol. 1986;11(6):579–83.CrossRefPubMedGoogle Scholar
  39. 39.
    Dicken CH, Powell ST, Spear KL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1984;11(3):500–2.CrossRefPubMedGoogle Scholar
  40. 40.
    Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology. 2009;218(2):134–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Boer J, van Gemert MJP. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40(1):73–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171(1):170–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164(1):170–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child bearing age. G Ital Dermatol Venereol. 2014 Jun 13. [Epub ahead of print].Google Scholar
  45. 45.
    Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg. 2007;11(4):125–31.CrossRefPubMedGoogle Scholar
  46. 46.
    Harrison BJ, Kumar S, Read GF, Edwards CA, Scanlon MF, Hughes LE. Hidradenitis suppurativa: evidence for an endocrine abnormality. Br J Surg. 1985;72(12):1002–4.CrossRefPubMedGoogle Scholar
  47. 47.
    Farrel AM, Ddawber RPR. Endocrine factors in pre- and postmenopausal women with hidradenitis Suppurativa. Br J Dermatol. 1997;136(5):802.CrossRefGoogle Scholar
  48. 48.
    Barth J, Layton A, Cunliffe W. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol. 1996;134(6):1057–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23(9):985–98.CrossRefPubMedGoogle Scholar
  50. 50.
    Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115(3):263–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatol Treat. 2005;16(2):75–8.CrossRefGoogle Scholar
  52. 52.
    Doménech C, Matarredona J, Escribano-Stablé JC, Devesa JP, Vicente J, Jaén A. Facial hidradenitis suppurativa in a 28-year-old male responding to finasteride. Dermatology. 2012;224(4):307–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Arun B, Loffeld A. Long-standing hidradenitis suppurativa treated effectively with metformin. Clin Exp Dermatol. 2009;34(8):920–1.CrossRefPubMedGoogle Scholar
  54. 54.
    Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27(9):1101–81.CrossRefPubMedGoogle Scholar
  55. 55.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–17.CrossRefPubMedGoogle Scholar
  57. 57.
    Paradela S, Rodríguez-Lojo R, Fernández-Torres R, Arévalo P, Fonseca E. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatol Treat. 2012;23(4):278–83.CrossRefGoogle Scholar
  58. 58.
    Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170(4):986–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Machet L, Samimi M, Delage M, Paintaud G, Maruani A. Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases. J Am Acad Dermatol. 2013;69(4):649–50.CrossRefPubMedGoogle Scholar
  60. 60.
    Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726–9.PubMedGoogle Scholar
  61. 61.
    Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A, et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol. 2010;19(6):538–40.CrossRefPubMedGoogle Scholar
  62. 62.
    Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60(4):565–73.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5):501–4.CrossRefPubMedGoogle Scholar
  64. 64.
    Pellegrino M, Taddeucci P, Peccianti C, Mei S, Fioravanti A, Fimiani M. Etanercept induced hidradenitis suppurativa. G Ital Dermatol Venereol. 2011;146(6):503–4.PubMedGoogle Scholar
  65. 65.
    Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145(5):580–4.CrossRefPubMedGoogle Scholar
  66. 66.
    Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49(8):950–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GBE. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–8.CrossRefPubMedGoogle Scholar
  68. 68.
    Kimball AB, Kerdal F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa. A parallel randomized trial. Ann Intern Med. 2013;157(12):846–55.CrossRefGoogle Scholar
  69. 69.
    Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26(7):911–4.CrossRefPubMedGoogle Scholar
  70. 70.
    Sharon VR, Garcia MS, Bagheri S, Goodarzi H, Yang C, Ono Y, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92(3):320–1.CrossRefPubMedGoogle Scholar
  71. 71.
    Santos-Pérez MI, García-Rodicio S, Del Olmo-Revuelto MA, Pozo-Román T. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr. 2014;105(7):720–2.CrossRefPubMedGoogle Scholar
  72. 72.
    Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(2):243–51.CrossRefPubMedGoogle Scholar
  73. 73.
    Zarchi K, Dufour DN, Jemec GBE. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149(10):1192–4.CrossRefPubMedGoogle Scholar
  74. 74.
    Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146(11):1265–70.CrossRefPubMedGoogle Scholar
  75. 75.
    Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)–a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66(3):409–15.CrossRefPubMedGoogle Scholar
  76. 76.
    Menis D, Maroñas-Jimenez L, Delgado-Marquez AM, Postigo-Llorente C, Vanaclocha-Sebastián F. Two cases of severe Hidradenitis Suppurativa with failure of anakinra therapy. Br J Dermatol. 2014 Jul 24. doi: 10.1111/bjd.13292.
  77. 77.
    Van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226(2):97–100.CrossRefPubMedGoogle Scholar
  78. 78.
    Rose RF, Goodfield MJD, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol. 2006;31(1):154–5.CrossRefPubMedGoogle Scholar
  79. 79.
    Bianchi L, Hansel K, Stingeni L. Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A. J Am Acad Dermatol. 2012;67(6):e278–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88(5):289P–90P.PubMedCentralPubMedGoogle Scholar
  81. 81.
    Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, Grifiths CE, Cooper KDVJ. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126(3):339–50.CrossRefPubMedGoogle Scholar
  82. 82.
    Jemec GBE. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27(6):528–9.CrossRefPubMedGoogle Scholar
  83. 83.
    De Souza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis. 2011;69(2):185–7.PubMedGoogle Scholar
  84. 84.
    Van der Zee HH, Prens EP. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology. 2011;223(2):169–73.CrossRefPubMedGoogle Scholar
  85. 85.
    Gold M, Bridges TM, Bradshaw VL, Boring M. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol. 2003;31:S32–5.Google Scholar
  86. 86.
    Rivard J, Ozog D. Henry Ford Hospital dermatology experience with Levulan Kerastick and blue light photodynamic therapy. J drugs dermatol. 2006;5(6):556–61. Google Scholar
  87. 87.
    Strauss RM, Pollock B, Stables GI, Goulden V, Cunliffe WJ. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol. 2005;152(4):803–4.CrossRefPubMedGoogle Scholar
  88. 88.
    Schweiger ES, Riddle CC, Aires DJ. Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. J Drugs Dermatol. 2011;10(4):381–6.PubMedGoogle Scholar
  89. 89.
    Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br J Dermatol. 1994;131(4):551–6.CrossRefPubMedGoogle Scholar
  90. 90.
    Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol. 2002;47(2):280–5.CrossRefPubMedGoogle Scholar
  91. 91.
    Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol. 1996;34(3):465–9.CrossRefPubMedGoogle Scholar
  92. 92.
    Madan V, Hindle E, Hussain W, August PJ. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol. 2008;159(6):1309–14.CrossRefPubMedGoogle Scholar
  93. 93.
    Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36(2):208–13.CrossRefPubMedGoogle Scholar
  94. 94.
    Krakowski AC, Admani S, Uebelhoer NS, Eichenfield LF, Shumaker PR. Residual scarring from hidradenitis suppurativa: fractionated CO2 laser as a novel and noninvasive approach. Pediatrics. 2014;133(1):e248–51.CrossRefPubMedGoogle Scholar
  95. 95.
    Highton L, Chan W-Y, Khwaja N, Laitung JKG. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011;128(2):459–65.CrossRefPubMedGoogle Scholar
  96. 96.
    Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009;35(8):1188–98.CrossRefPubMedGoogle Scholar
  97. 97.
    Mahmoud BH, Tierney E, Hexsel CL, Pui J, Ozog DM, Hamzavi IH. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010;62(4):637–45.CrossRefPubMedGoogle Scholar
  98. 98.
    Xu LY, Wright DR, Mahmoud BH, Ozog DM, Mehregan DA, Hamzavi IH. Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment. Arch Dermatol. 2011;147(1):21–8 (American Medical Association).CrossRefPubMedGoogle Scholar
  99. 99.
    Jain V, Jain A. Use of lasers for the management of refractory cases of hidradenitis suppurativa and pilonidal sinus. J Cutan Aesthet Surg. 2012;5(3):190–2.CrossRefPubMedCentralPubMedGoogle Scholar
  100. 100.
    Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621–3.CrossRefPubMedGoogle Scholar
  101. 101.
    Esmann SJG. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91(3):328–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Rosalind Hughes
    • 1
  • Genevieve Kelly
    • 1
  • Cheryl Sweeny
    • 2
  • Aoife Lally
    • 1
  • Brian Kirby
    • 1
  1. 1.Department of DermatologySt. Vincent’s University HospitalDublin 4Ireland
  2. 2.Dermatology Research Group, Education and Research CentreSt. Vincent’s University HospitalDublinIreland

Personalised recommendations